Evidence-based recommendations on primary treatment of carcinomas of the breast consensus of the AGO organ commission "mamma";Evidenzbasierte empfehlungen zur primärbehandlung von mammakarzinomen: Der konsens der AGO-organkommission "mamma"

Zentralblatt fur Gynakologie

Volumn 124, Issue 5, 2002, Pages 293-303

  Von Minckwitz, G ^a   Brunnert, K ^a   Costa, S D ^a   Friedrichs, K ^a   Jackisch, Ch ^a   Gerber, B ^a   Harbeck, N ^a   Junkermann, H ^a   Mobus V ^a   Nitz, U ^a   Schaller, G ^a   Scharl, A ^a   Thomssen, Ch ^a   Untch, M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GONADORELIN DERIVATIVE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MASTECTOMY; OVARIECTOMY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADULT; AGED; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; PROGNOSIS;

EID: 16744364822     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34095     Document Type: Article

References (72)

1. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology
2. Preventive health care, 1999 update: 3. Follow-up after breast cancer
3. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
4. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
5. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I
6. Tamoxifen for early breast cancer: An overview of the randomized trials
7. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridisation
8. The requirements of a specialist breast unit
9. Quality assurance in the diagnosis of breast disease
10. Position paper EUSOMA guidelines: Quality control in the locoregional treatment of breast cancer
11. Staging investigations in patients with breast cancer: The role of bone scans and liver imaging
12. The importance of the resection margin in conservative surgery for breast cancer
13. Principles and guidelines for surgeons - Management of symptomatic breast cancer
14. Factors affecting outcome of patients with impalpable breast cancer detected by breast screening
15. A contemporary view of axillary dissection
16. Should irradiation replace dissection for patients with breast cancer with clinically negative axillary lymph nodes?
17. Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link
18. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes
19. Axillary lymph node metastases associated with small invasive breast carxinomas
20. Mammary ductal carcinoma in situ with microinvasion
21. Tumor-specific immediate reconstruction (TSIR) in breast cancer patients
22. Local recurrence risk after skin-sparing and conventional mastectomy: A 6-year follow-up
23. Immediate reconstruction with mammaplasty in conservative breast cancer treatment: Long-term results
24. Radiation therapy after immediate breast reconstruction with implants
25. The effects of radiation after TRAM flap breast reconstruction
26. Incidence of and treatment for ductal carcinoma in situ of the breast
27. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy
28. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853
29. Prognostic classification of breast ductal carcinoma-in-situ
30. The influence of margin width on local control of ductal carcinoma in situ of the breast
31. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
32. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomized phase III trial 10853
33. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
34. Polychemotherapy for early breast cancer: An overview of the randomized trials
35. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC)
36. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
37. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
38. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherepy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
39. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
40. The ATAC (Arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal women
41. Ovarian ablation for early breast cancer
42. The emerging role of hormonal ablation
43. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four year results of ABCSG trial 5
44. Management of stage III breast cancer
45. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
46. Management of breast cancer during pregnancy using a standardized protocol
47. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
48. Use of chemotherepy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
49. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
50. Safety profile of Herceptin as a single agent and in combination with chemotherapy
51. Cisplatin as first-line therapy for metastatic breast cancer
52. Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule
53. Texotere, cisplatin and herceptin (TCH) in first-line HER2 Positive Metastatic Breast Cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101)
54. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
55. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
56. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial
57. A randomized placebo controlled trial to evaluate the effect of the bisphosphonate, clodronate, on the incidence of metastases and mortality in patients with primary operable breast cancer
58. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
59. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation
60. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial
61. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation
62. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology
63. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials
64. The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial
65. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer
66. Impact of participation in randomized clinical trials on survival of women with early-stage breast cancer - An analysis of 7985 patients
67. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials
68. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
69. The effect on primary tumor response of adding sequential taxotere to adriamycin and cylophosphamide: Preliminary results from NSABP Protocol B-27